Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

Inflammation Segment: Provides Cash Flow to Support Investments in Our Orphan and Rheumatology Medicines . Four medicines: - PENNSAIDⓇ 2%: indicated for treatment of OA of the knee RAYOS® indicated for treatment of multiple conditions, including rheumatoid arthritis (RA) and polymyalgia rheumatica DUEXISⓇ and VIMOVO®: indicated for treatment of osteoarthritis (OA) and RA PENNSAID (diclofenac sodium topical solution) 2% w/w RAYOS® (Prednisone) Delayed-release Tablets DUEXIS (ibuprofen and famotidine) Tablets 800 mg/26.6 mg HORIZON VIMOVO® (naproxen/esomeprazole magnesium) 37

View entire presentation